FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis

Researchers identified FBXO32 as an oncogenic driver in PDAC. FBXO32 was aberrantly upregulated in PDAC, and high FBXO32 expression was significantly associated with an unfavorable prognosis in PDAC patients.